10.3171/jns.2000.92.3.0413 44
Collectively, these findings raise the possibility that the mechanism of glucocorticoids increasing serum IGF-I levels is by directly inducing post-IGF-IR signaling resistance
MondoA-Thioredoxin-Interacting Protein Axis Maintains Regulatory T-Cell Identity and Function in Colorectal Cancer Microenvironment
Lexaria Announces Positive Final Results From Human Pilot Study #5 February 5, 2026 Company Further Examining the Pursuit of the Worlds First Oral Liraglutide Product Lexaria Awarded Six Additional Patents January 22, 2026 Lexaria now has 60 patents granted around much of the world Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 December 30, 2025 Additional secondary and exploratory endpoint final results update on its Phase 1b, 12-week chronic study GLP-1-H24-4 Primary Endpoint Successfully Achieved in Lexarias Phase 1b Study GLP-1-H24-4 December 23, 2025 DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus Recent financings create runway for prospective new 2026 development opportunities Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended November 12, 2025 Lexaria provides update on the Material Transfer Agreement (MTA) originally entered into on September 4, 2024 Lexarias Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain September 19, 2025 Enhanced Brain Biodistribution of GLP-1 Drugs May Be Related to Improvements in Safety and Efficacy Lexarias Phase 1b GLP-1 Study Achieves Important Last Patient Last Visit Milestone August 14, 2025 Lexarias contract research organization has completed the important study milestone known as last patent last visit (LPLV) in Lexarias Phase 1b glucagon-like peptide-1 study in Australia, GLP-1-H24-4 Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study July 28, 2025 DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus DehydraTECH-GLP-1 study arms evidencing patient safety and tolerability consistent with the primary study endpoint Lexaria Reaches Patent Milestone 50 Patents Now Granted Worldwide June 23, 2025 New patents received for the treatment of epilepsy and for the sublingual delivery of nicotine Lexarias DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule June 11, 2025 Oral DehydraTECH-liraglutide showed a pronounced reduction in adverse events (AEs) as compared to injected liraglutide (Saxenda) Lexaria has now demonstrated, in distinct human clinical studies, clear reductions in AEs utilizing its patented DehydraTECH technology with all of the three major GLP-1 drugs sold in the world today: liraglutide, semaglutide and tirzepatide Lexarias Human GLP-1 Study #5 Begins Dosing April 2, 2025 Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutide Lexarias DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lillys Injectable Zepbound March 18, 2025 Lexarias DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lillys Injectable Zepbound More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound As previously announced, oral DehydraTECH-tirzepatide also reduced adverse events by 47% compared to injected Zepbound Lexarias oral capsules worthy of expanded investigation as a viable alternative to injected tirzepatide
They are temporary inconveniences that confirm the mechanism is active
